Key result
Brentuximab single-agent therapy resulted in an unsustained clinical response in a patient with CD30-positive angiosarcoma.
Brentuximab single agent therapy may not provide a sustained response in CD30 positive angiosarcoma.
Answers are grounded in this paper and cite their sources.
Transient response cautions against single-agent brentuximab for durable control; leaves open need for combinations or prospective trials.
Angiosarcoma (AS) is a rare and often high-grade malignant vascular tumor [1]. They represent below 2% of all soft tissue sarcomas and present in a broad variety of anatomic locations [1,2]. Predis...
No takes yet. Share an insight, caveat, or question.
Holm et al. (2015) studied this question. Brentuximab single-agent therapy resulted in an unsustained clinical response in a patient with CD30-positive angiosarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: